197723-00-5
基本信息
CS-2765
KP 1339
NKP-1339
KP1339
KP 1339
NKP1339
NKP 1339
KP-1339
物理化学性质
| 储存条件 | -20°C储存 |
| 溶解度 | 可溶于乙醇 |
| 形态 | 固体 |
| 颜色 | Light brown to khaki |
CS-2765价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2023/03/20 | HY-16350 | CS-2765 NKP-1339 | 197723-00-5 | 5mg | 3500元 |
| 2023/03/20 | HY-16350 | CS-2765 NKP-1339 | 197723-00-5 | 10mM * 1mLin DMSO | 3866元 |
| 2023/03/20 | HY-16350 | CS-2765 NKP-1339 | 197723-00-5 | 10mg | 5000元 |
常见问题列表
Apoptosis
NKP-1339 (0-200 μM; 72 hours) has the anticancer activity against malignant cell lines of diverse origin, exhibits IC 50 values of 45-200 μM for KP1339 mono-therapy. It against Hepatoma cell line, Hep3B, HepG2, PLC/PRF/5 and HCC2 cells with the Mean IC 50 value of 186.3 μM, 165.4 μM, 124.4 μM, and 69.4 μM, respectively. It against Melanoma cell line, VM-1, VM-21,VM-48 with IC 50 values of 178 μM, 111 μM, and 143 μM, respectively. It against Lung cancer and Colon cancer cell lines, inhibits A549, VL-8, SW480 and HCT116 cells, respectively. NKP-1339 (0-150 μM; 24 hours) induces cell apoptosis alone. When it combines with sorafenib, it increases the numbers of the apopotic cells. Additionally, the p-PARP and caspase 7 cleavage is promoted either. NKP-1339 (0-150 μM; 24 hours) can promote phosphorylation of STAT3 and CREB expression, however, the decreasation is inhibited by sorafenib cotreatment.
Cell Viability Assay
| Cell Line: | Hepatoma, Melanoma, Lung cancer and Colon cancer cell lines |
| Concentration: | 0 μM, 50 μM, 100 μM, 150 μM and 200 μM |
| Incubation Time: | 72 hours |
| Result: | Has anti-cancer activity in diverse malignant tumour cell types. |
Apoptosis Analysis
| Cell Line: | Hep3B cells |
| Concentration: | 0 μM, 75 μM, 150 μM |
| Incubation Time: | 72 hours |
| Result: | Promoted cell apoptosis as a concentration manner. |
Western Blot Analysis
| Cell Line: | Hep3B cells |
| Concentration: | 0 μM, 75 μM, 150 μM |
| Incubation Time: | 72 hours |
| Result: | Increased p-STAT3 and p-CREB expression in cells without sorafenib cotreatment. |
NKP-1339 (intravenous injection; 30 mg/kg; once a week; 42sdays) combines with the multi-kinase inhibitor sorafenib and exhibits a further anticancer activity when compares to the NKP-1339 treatment alone in Hep3B xenografts grown in Balb/c SCID mice .
| Animal Model: | Hep3B xenograft in Balb/c mice |
| Dosage: | 30 mg/kg |
| Administration: | Intravenous injection |
| Result: | Had synergistic activity of KP1339 with sorafenib in vivo. |